PR Pitching & Outreach Software | Free 7-day Trial

ionicons-v5-p Product[1] Pricing[2] Customers[3] Resources[4] ionicons-v5-l Sign in[5] Sign up for free[6] References ^ Product (prowly.com) ^ Pricing (prowly.com) ^ Customers (prowly.com) ^ Resources (prowly.com) ^ Sign in (app.prowly.com) ^ Sign up for free.css-1od5yty{padding-left:9px;}.css-1od5yty path{-webkit-transition:fill 250ms ease-out;transition:fill 250ms ease-out;} (app.prowly.com) Read Article to Me (Mobile Version) Source URL: Read More The public content above was dynamically discovered – by graded...

READ MORE PR Pitching & Outreach Software | Free 7-day Trial

Press Release Software & Creator

ionicons-v5-p Product[1] Pricing[2] Customers[3] Resources[4] ionicons-v5-l Sign in[5] Sign up for free[6] References ^ Product (prowly.com) ^ Pricing (prowly.com) ^ Customers (prowly.com) ^ Resources (prowly.com) ^ Sign in (app.prowly.com) ^ Sign up for free.css-1od5yty{padding-left:9px;}.css-1od5yty path{-webkit-transition:fill 250ms ease-out;transition:fill 250ms ease-out;} (app.prowly.com) Read Article to Me (Mobile Version) Source URL: Read More The public content above was dynamically discovered – by graded...

READ MORE Press Release Software & Creator

Press Releases

Thermo Fisher Scientific Expands Direct-to-Patient Clinical Trials Service Offerings End-to-end solution accelerates clinical trials with speed, convenience and quality WALTHAM, Mass., Oct. 27, 2020 /PRNewswire[1]/ — A newly expanded Direct-to-Patient service offering supports decentralized clinical trials to minimize clinical trial length and costs while maximizing patient enrollment and participation rates. The comprehensive offering now includes Clinical Site-to-Patient, Pharmacy-to-Patient and Depot-to-Patient...

READ MORE Press Releases

Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19

— Study Demonstrates Similar Efficacy with 5- and 10-Day Dosing Durations of Remdesivir — FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalized patients with severe manifestations of COVID-19 disease. The study demonstrated that patients receiving...

READ MORE Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19

Generated by Feedzy